Slide 1: Q1:23 Results Conference Call
Exhibit 99.2 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Q1:23 Results Conference Call May 2, 2023
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 th
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer 4
Slide 5: Q1:23 Highlights
Q1:23 Highlights • Superb execution across the Net Sales Gross Margin organization, especially by the commercial team, with net sales of $71.7 million, net loss of $5.0 million and Adjusted EBITDA of $5.5 $71.7MM 82.7% million • Q1:23 results demonstrate Year/Year Growth Adjusted EBITDA that we are
Slide 6: Progress Executing on Strategic Priorities
Progress Executing on Strategic Priorities Build leadership position in Develop opportunities in Demonstrate corporate Wound & Surgical discipline around expenses adjacent markets • Seeking to be deeper and • Goal to become more • Growth in all sites-of-service in Q1 wider in the markets we profitab
Slide 7: Pete Carlson, Chief Financial Officer
Pete Carlson Chief Financial Officer 7
Slide 8: Q1:23 Net Sales
Q1:23 Net Sales • Q1:23 net sales growth of 2023 Quarterly Shipping Day Net Sales 21.7% compared to Q1:22 Variance vs. 2022 $71.7 • Strong performance $58.9 +1 despite industry seasonality (e.g., deductible re-sets, lower patient traffic, 0 etc.) -1 -1 • Q1:23 net sales benefitted from one additiona
Slide 9: Q1:23 Gross Profit & Gross Margins
Q1:23 Gross Profit & Gross Margins • Q1:23 gross margins roughly flat year-over-year and up $60.0 $59.3 200 bp sequentially, $55.5 $55.1 reversing a downward trend $49.0 over the past several quarters 83.1% 82.7% 82.3% 82.0% • Improving gross margin 80.7% remains a top priority; continue to believe
Slide 10: Q1:23 Operating Expenses
Q1:23 Operating Expenses $52.3 Q1:22 $49.6 Q1:23 • Significant actions taken to improve Company’s cost base beginning to $6.5 materialize in Q1:23 $6.0 SG&A R&D • Focused on demonstrating expense $5.5 control and improving profitability in 2023 and beyond -$1.7 -$5.0 -$10.5 Adjusted EBITDA Net Incom
Slide 11: Q1:23 Results by Business Segment
Q1:23 Results by Business Segment Wound & Surgical ($ millions) Q1:21 Q1:22 Q1:23 Net Sales $51.4 $58.3 $70.6 • Q1:23 Wound & Surgical segment contribution of Cost of Sales (7.2) (9.1) (11.3) $20.1 million or 28.4% of Wound & Surgical net sales (25.8) (34.0) (37.7) Selling, General and Administrativ
Slide 12: Cash Balance at March 31, 2023
Cash Balance at March 31, 2023 • Q1 cash use driven by payment of annual employee incentive compensation and ongoing investments in working capital to fund growth • Expect to build cash over the course of 2023 $61.2MM • Do not currently anticipate need for external financing to fund operations or lo
Slide 13: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer 13
Slide 14: Summary Q1:23 Highlights
Summary Q1:23 Highlights Include: Q1:23 Net Sales Growth of Nearly 22% Year-Over-Year Gross Profit of 82.7% Adjusted EBITDA of $5.5 Million Off to a Strong Start Continued Roll Out of New Products in the U.S. in 2023! Initial Sales of EPIFIX in Japan Focus on Driving Efficiency and Expense Rationali
Slide 15: Generating Sustainable Profitability & Strengthening our Balance Sheet
Generating Sustainable Profitability & Strengthening our Balance Sheet TURN • Milestone payment related to FDA clearance of FleX product no longer expected in 2023 Therapeutics Legal • Nearing the conclusion of legal expense overhang related legacy indemnity fees and Expenses* related costs Expect t
Slide 16: Closing Remarks and Q&A
Closing Remarks and Q&A MIMEDX